이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Repare Therapeutics 관리
관리 기준 확인 2/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Lloyd Segal
최고 경영자
US$5.0m
총 보상
| CEO 급여 비율 | 12.3% |
| CEO 임기 | 8yrs |
| CEO 소유권 | 0.3% |
| 경영진 평균 재임 기간 | 5.3yrs |
| 이사회 평균 재임 기간 | 4.8yrs |
최근 관리 업데이트
Recent updates
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
Aug 30Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?
Jul 12
Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Mar 12We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
Feb 15Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth
Dec 20Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Oct 24New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)
Aug 14Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week
May 14Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results
May 12Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough
May 08Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%
Mar 03Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Oct 27Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Sep 07Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Aug 04Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
Jun 27Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Jun 24Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans
Mar 02We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn
Oct 14We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Apr 16Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?
Mar 12Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?
Feb 08
Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies
Dec 28Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently
Dec 21We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Nov 19CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$69m |
| Mar 31 2024 | n/a | n/a | -US$46m |
| Dec 31 2023 | US$5m | US$615k | -US$94m |
| Sep 30 2023 | n/a | n/a | -US$97m |
| Jun 30 2023 | n/a | n/a | -US$3m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$4m | US$592k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$26m |
| Jun 30 2022 | n/a | n/a | -US$132m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$4m | US$572k | -US$107m |
| Sep 30 2021 | n/a | n/a | -US$94m |
| Jun 30 2021 | n/a | n/a | -US$77m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$5m | US$505k | -US$53m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$2m | US$430k | -US$27m |
보상 대 시장: Lloyd 의 총 보상 ($USD 4.99M )은 US 시장( $USD 1.62M ).
보상과 수익: 회사가 수익성이 없는 동안 Lloyd 의 보상이 증가했습니다.
CEO
Lloyd Segal (60 yo)
8yrs
테뉴어
US$4,991,804
보상
Mr. Lloyd Mitchell Segal serves as Director at HotKnot Therapeutics, Inc. Mr. Segal has been the Chief Executive Officer, President and Director of Repare Therapeutics Inc. since September 2016. Mr. Segal...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 8yrs | US$4.99m | 0.28% $ 405.5k | |
| Executive VP & CFO | 4.9yrs | US$1.93m | 0.034% $ 49.6k | |
| Executive VP & Chief Medical Officer | 5.3yrs | US$2.09m | 0.47% $ 687.2k | |
| Co-Founder | no data | 데이터 없음 | 데이터 없음 | |
| Co-Founder | no data | 데이터 없음 | 데이터 없음 | |
| Co-Founder | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief Scientific Officer | 5.3yrs | US$1.83m | 0.098% $ 142.9k | |
| Executive Vice President of Human Resource | 1.3yrs | 데이터 없음 | 0.0037% $ 5.4k | |
| Executive Vice President of Discovery | 8.3yrs | 데이터 없음 | 0.055% $ 80.6k | |
| Executive VP | 2.7yrs | 데이터 없음 | 0.0092% $ 13.5k |
5.3yrs
평균 재임 기간
53yo
평균 연령
경험이 풍부한 관리: RPTX 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 8yrs | US$4.99m | 0.28% $ 405.5k | |
| Independent Director | 4.3yrs | US$274.74k | 0.0094% $ 13.8k | |
| Independent Director | 5yrs | US$265.41k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$664.86k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$268.78k | 0% $ 0 | |
| Independent Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Independent Director | 4.8yrs | US$265.31k | 0% $ 0 | |
| Independent Chairman | 3yrs | US$291.49k | 0.018% $ 25.8k | |
| Independent Director | 5.5yrs | US$272.99k | 0.019% $ 27.5k |
4.8yrs
평균 재임 기간
59yo
평균 연령
경험이 풍부한 이사회: RPTX 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.